Research Identifies Novel Longevity Peptide in Centenarians
Scientists discover a mitochondrial-derived peptide at elevated levels in centenarians, potentially opening new avenues for understanding healthy aging.
Researchers announced this week the identification of a novel mitochondrial-derived peptide that appears at significantly elevated levels in individuals who live past 100 years. The discovery, published in a leading aging research journal, adds to the growing body of evidence that small peptides encoded within mitochondrial DNA may play important roles in longevity and metabolic health.
What We Know
The research team analyzed blood samples from 850 centenarians enrolled in the New England Centenarian Study, comparing peptide profiles to age-matched controls and younger adults [nature-aging-2025]. Using advanced mass spectrometry techniques, they identified a 24-amino acid peptide derived from the mitochondrial genome at levels approximately 2.5-fold higher in centenarians compared to 70-year-old controls.
The peptide, tentatively named SHLP-8 (Small Humanin-Like Peptide 8), shares structural features with other known mitochondrial-derived peptides including humanin and MOTS-c. Functional studies in cell culture demonstrated that SHLP-8 enhances mitochondrial function, reduces oxidative stress markers, and modulates inflammatory signaling pathways [centenarian-study].
Critically, the elevated levels in centenarians appeared to be associated with better cognitive function and physical performance measures. Centenarians in the highest quartile for SHLP-8 levels scored significantly better on tests of executive function and had faster walking speeds compared to those in the lowest quartile.
The Mitochondrial-Derived Peptide Family
SHLP-8 joins a growing family of small peptides encoded within mitochondrial DNA that appear to have signaling functions beyond the mitochondrion’s traditional role in energy production [mdp-review].
Humanin, discovered in 2001, was the first such peptide identified and has been linked to neuroprotection and insulin sensitivity. MOTS-c, identified more recently, regulates metabolic homeostasis and has been called an “exercise mimetic” for its effects on muscle function. The SHLP family (Small Humanin-Like Peptides) includes several members with varying tissue distributions and functions.
The evolutionary conservation of these peptides across species suggests fundamental biological importance. Researchers hypothesize that mitochondrial-derived peptides may serve as signals of mitochondrial health, communicating the energy-producing capacity of cells to other tissues and systems.
What It Means
The identification of SHLP-8 has both scientific and translational implications.
Scientific understanding: The finding supports the mitochondrial theory of aging, which posits that accumulated mitochondrial dysfunction contributes to age-related decline. If certain peptides can preserve mitochondrial function, understanding their biology could illuminate fundamental aging processes.
Biomarker potential: SHLP-8 levels could serve as a biomarker for healthy aging or longevity potential. However, whether the peptide is causally involved in longevity or simply a marker of other protective factors requires further study.
Therapeutic development: If SHLP-8 proves functionally important, synthetic versions could potentially be developed as therapeutics. Other mitochondrial-derived peptides, including humanin analogs, are already in preclinical development for conditions ranging from Alzheimer’s disease to metabolic syndrome.
The researchers emphasize several important caveats. The study demonstrates association, not causation. Centenarians have many genetic and lifestyle factors that contribute to their longevity, and SHLP-8 may be a consequence rather than a cause of healthy aging. Additionally, the sample, while large for centenarian research, may not be representative of all populations.
What’s Next
The research team has outlined several follow-up studies to advance understanding of SHLP-8’s role in aging.
Mechanistic studies: Laboratory research will examine how SHLP-8 affects cellular processes including autophagy, senescence, and stress resistance. These studies will help establish whether the peptide has direct protective effects.
Longitudinal tracking: Following individuals over time to see whether SHLP-8 levels predict survival and healthy aging would strengthen the case for its importance.
Genetic analysis: Identifying genetic variants that affect SHLP-8 levels could provide additional evidence for causality and reveal regulatory mechanisms.
Synthetic peptide development: Creating synthetic versions of SHLP-8 with improved stability and potency would enable more extensive preclinical testing.
Animal studies: Testing whether SHLP-8 administration extends lifespan or healthspan in model organisms would be an important step toward therapeutic development.
The broader longevity research field continues to advance rapidly, with multiple approaches including senolytics, NAD+ precursors, and now mitochondrial-derived peptides showing promise. The integration of these findings into a comprehensive understanding of aging biology remains an ongoing challenge.
This information is provided for educational purposes only and does not constitute medical advice. Longevity research is in early stages, and no therapies based on these findings are currently available.
Sources & Citations
- 1journalIdentification of a Novel Mitochondrial Peptide Associated with Extreme Longevity
nature-aging-2025
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.